D ynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

Dynavax Technologies (NASDAQ:DVAX) added ~7% in the premarket on Thursday after the company said that its experimental ...

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

Dynavax’s lofty ambition to snatch Shingrix’s crown got off to a promising start after the biopharma’s investigational shingles vaccine held its own against GSK’s mainstay in the first part of a phase ...

Shares in Dynavax Technologies Corporation closed 5% higher Thursday after the presentation of positive top-line results from ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

Dynavax's Z-1018 shingles vaccine matched Shingrix in immune response with fewer side effects, advancing to Phase 2 in older adults in 2025.

Shares of Dynavax rose after the company released positive results from a trial of its shingles vaccine tested against current Shingles vaccine Shingrix. The stock was up 6.7% to $11.12 but is still ...

GSK's Shingrix New Prefilled Syringe Presentation Accepted For Review By FDA January 10, 2025 — 02:29 am EST Written by RTTNews.com for RTTNews -> ...

GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX Sep. 18, 2024 7:00 AM ET GSK plc (GSK), AGEN ...

GSK’s Shingrix has been the only FDA-approved shingles vaccine since Merck stopped selling its option in 2020. Arexvy first hit the scene last year along with Pfizer’s rival Abrysvo.

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified. See what to expect from GSK's Q3.